Liver transplant in patients with primary sclerosing cholangitis: A retrospective cohort from Northeastern Brazil

Table 1 Clinical and socioepidemiological variables of patients with primary sclerosing cholangitis submitted to liver transplantation between 2012 and 2022

Variables	n	Total1	Females (n = 141)	Males (n = 191)	P value2
Age at LTx, yr	32	40 ± 14 (36)	43 ± 13 (39)	38 ± 14 (35)	0.347
Age at first symptom, yr	30	32 ± 14 (30)	35 ± 13 (36)	30 ± 14 (29)	0.498
Age at IBD diagnosis, yr	17	35 ± 14 (32)	37 ± 18 (42)	33 ± 12 (30)	0.370
Months between 1st symptom and 1st consultation	26	18 ± 37 (2)	16 ± 33 (3)	19 ± 39 (2)	0.616
Months between onset of symptoms and diagnosis	31	80 ± 235 (23)	148 ± 357 (56)	31 ± 41 (13)	0.155
Baseline clinical symptoms
Jaundice	32	29 (91%)	11 (85%)	18 (95%)	0.552
Pruritus	32	25 (74%)	6 (24%)	19 (76%)
Fever + shivering	32	14 (44%)	5 (38%)	9 (47%)	0.618
Weight loss	32	18 (56%)	9 (69%)	9 (47%)	0.221
Fatigue	32	13 (41%)	6 (46%)	7 (37%)	0.598
PSC classification
Classic PSC	31	30 (97%)	12 (92%)	18 (100%)	0.419
PSC + AIH	31	3 (9.7%)	3 (23%)	0 (0%)	0.064
Small-duct PSC	31	1 (3.2%)	0 (0%)	1 (5.6%)	> 0.999
Diagnostic testing
MRCP realized	32	23 (72%)	10 (77%)	13 (68%)	0.704
MRCP	32	20 (62%)	10 (77%)	10 (53%)	0.163
ERPC	32	12 (38%)	3 (23%)	9 (47%)	0.163
Biopsy	31	20 (65%)	7 (54%)	13 (72%)	0.449
Comorbidities
Diabetes	32	7 (22%)	2 (15%)	5 (26%)	0.671
Hypertension	32	6 (19%)	4 (31%)	2 (11%)	0.194
Dyslipidemia	32	4 (12%)	2 (15%)	2 (11%)	> 0.999
Obesity	32	1 (3.1%)	0 (0%)	1 (5.3%)	> 0.999
Smoking	32	4 (12%)	2 (15%)	2 (11%)	> 0.999
Drinking	32	6 (19%)	2 (15%)	4 (21%)	> 0.999
Others	31	8 (26%)	2 (17%)	6 (32%)	0.433
IBD	18				> 0.999
Ulcerative rectocolitis		15 (83%)	7 (88%)	8 (80%)
Crohn’s disease		3 (17%)	1 (12%)	2 (20%)
Ankylosing spondylitis	32	0 (0%)	0 (0%)	0 (0%)
Seronegative arthritis	32	0 (0%)	0 (0%)	0 (0%)
Gallbladder calculus	32	7 (22%)	3 (23%)	4 (21%)	> 0.999
Gallbladder polyps	31	0 (0%)	0 (0%)	0 (0%)
Neoplasia	31	4 (13%)	2 (15%)	2 (11%)	> 0.999
Dyslipidemia	32	4 (12%)	2 (15%)	2 (11%)	> 0.999
Obesity	32	1 (3.1%)	0 (0%)	1 (5.3%)	> 0.999
Smoking	32	4 (12%)	2 (15%)	2 (11%)	> 0.999
Drinking	32	6 (19%)	2 (15%)	4 (21%)	> 0.999
Other	31	8 (26%)	2 (17%)	6 (32%)	0.433
Treatment
Ursodeoxycholic acid	29	27 (93%)	11 (92%)	16 (94%)	0.665
Prednisone	27	14 (52%)	9 (75%)	5 (33%)	0.031
Endoscopic treatment	16	8 (50%)	1 (12%)	7 (88%)	0.010
Indication for LTx					> 0.999
Untreatable pruritus		4 (12%)	2 (15%)	2 (11%)
Decompensated cirrhosis		27 (84%)	11 (85%)	16 (84%)
Hepatocellular carcinoma		1 (3.1%)	0 (0%)	1 (5.3%)
Dominant stenosis	26	4 (15%)	1 (9.1%)	3 (20%)	0.614

¹Range; mean ± SD (median); n (%).

²Wilcoxon rank sum exact test; Wilcoxon rank sum test; Fisher’s exact test; Pearson’s χ² test.

AIH: Autoimmune hepatitis; ERCP: Endoscopic retrograde cholangiopancreatography; IBD: Inflammatory bowel disease; LTx: Liver transplantation; PSC: Primary sclerosing cholangitis; MRCP: Magnetic resonance cholangiopancreatography.